Guggenheim Maintains Ionis Pharmaceuticals Buy Rating, Adjusts Price Target
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
Stocks · News reference
Ionis Pharmaceuticals and its partner Biogen reported new two-year data from the Phase 2 CELIA study showing clinical benefit for diranersen in early Alzheimer's disease.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
The European Commission has authorized TRYNGOLZA™ (olezarsen) as an adjunct to diet and lipid-lowering therapies for adult patients with severe hypertriglyceridemia.
Multiple financial institutions, including Morgan Stanley, Barclays, Wells Fargo, TD Cowen, and BMO Capital, updated their ratings and price targets for Ionis Pharmaceuticals on November 14, 2026.
Ionis Pharmaceuticals announced new long-term efficacy and safety data for its RNA-targeted hereditary angioedema (HAE) medicine, DAWNZERA® (donidalorsen), at the 2026 ACAAI Annual Scientific Meeting.
Barclays has lowered its price target for Ionis Pharmaceuticals from $85 to $70 while maintaining an Overweight rating on the stock.